Joy C Bunt1, Jonathan Krakoff, Emilio Ortega, William C Knowler, Clifton Bogardus. 1. Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Phoenix, Arizona 85016, USA. jbunt@mail.nih.gov
Abstract
BACKGROUND: Earlier prospective studies have identified insulin action and secretion as predictors of T2DM in populations with normal glucose tolerance (NGT) and impaired glucose tolerance (IGT) (2-h OGTT < 7.8 and 7.8-11 mmol/L, respectively). Fasting plasma glucose (FPG), an additional and recently modified (normal <5.6 mmol/L) diagnostic criterion is associated with insulin secretion. We wanted to establish whether insulin secretion persists as an independent predictor of T2DM in individuals with no clinical evidence of impaired glucose regulation based on FPG and 2-h plasma glucose concentrations. METHODS: Insulin action (M, euglycemic-hyperinsulinemic clamp), insulin secretion (acute insulin response (AIR), IVGTT), and adiposity (%Fat, DXA or densitometry) were compared at baseline in 358 Pima Indians (232M/126F, 18-44 years old) with normal glucose regulation of whom 61 (35M/26F) developed diabetes (DIAB) during a median follow-up time of 7.6 years. RESULTS: In proportional-hazard analysis, % Fat (HR = 1.52, p = 0.03), M (HR = 0.51, p = 0.04) and AIR (HR = 0.64, p = 0.003) predicted the development of diabetes after adjustment for age and sex. In regression analysis adjusting for age, sex, %Fat and M at baseline, the non-diabetic group (NON-DM) had a higher AIR (p = 0.0002) than the DIAB group; the positive association of AIR with adiposity observed in the NON-DM group was absent in the DIAB group. Cumulative incidence rates (12y) for diabetes were highest (48%) in subjects with both M and AIR below the population median and lowest (11%) in subjects with both M and AIR above the population median. CONCLUSION: AIR can predict diabetes prior to the current clinical indicators of impaired glucose regulation. Published in 2006 by John Wiley & Sons, Ltd. John Wiley & Sons, Ltd.
BACKGROUND: Earlier prospective studies have identified insulin action and secretion as predictors of T2DM in populations with normal glucose tolerance (NGT) and impaired glucose tolerance (IGT) (2-h OGTT < 7.8 and 7.8-11 mmol/L, respectively). Fasting plasma glucose (FPG), an additional and recently modified (normal <5.6 mmol/L) diagnostic criterion is associated with insulin secretion. We wanted to establish whether insulin secretion persists as an independent predictor of T2DM in individuals with no clinical evidence of impaired glucose regulation based on FPG and 2-h plasma glucose concentrations. METHODS:Insulin action (M, euglycemic-hyperinsulinemic clamp), insulin secretion (acute insulin response (AIR), IVGTT), and adiposity (%Fat, DXA or densitometry) were compared at baseline in 358 Pima Indians (232M/126F, 18-44 years old) with normal glucose regulation of whom 61 (35M/26F) developed diabetes (DIAB) during a median follow-up time of 7.6 years. RESULTS: In proportional-hazard analysis, % Fat (HR = 1.52, p = 0.03), M (HR = 0.51, p = 0.04) and AIR (HR = 0.64, p = 0.003) predicted the development of diabetes after adjustment for age and sex. In regression analysis adjusting for age, sex, %Fat and M at baseline, the non-diabetic group (NON-DM) had a higher AIR (p = 0.0002) than the DIAB group; the positive association of AIR with adiposity observed in the NON-DM group was absent in the DIAB group. Cumulative incidence rates (12y) for diabetes were highest (48%) in subjects with both M and AIR below the population median and lowest (11%) in subjects with both M and AIR above the population median. CONCLUSION: AIR can predict diabetes prior to the current clinical indicators of impaired glucose regulation. Published in 2006 by John Wiley & Sons, Ltd. John Wiley & Sons, Ltd.
Authors: J F Gautier; C Wilson; C Weyer; D Mott; W C Knowler; M Cavaghan; K S Polonsky; C Bogardus; R E Pratley Journal: Diabetes Date: 2001-08 Impact factor: 9.461
Authors: F de Vegt; J M Dekker; A Jager; E Hienkens; P J Kostense; C D Stehouwer; G Nijpels; L M Bouter; R J Heine Journal: JAMA Date: 2001-04-25 Impact factor: 56.272
Authors: J Tuomilehto; J Lindström; J G Eriksson; T T Valle; H Hämäläinen; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; M Laakso; A Louheranta; M Rastas; V Salminen; M Uusitupa Journal: N Engl J Med Date: 2001-05-03 Impact factor: 91.245
Authors: C Weyer; T Funahashi; S Tanaka; K Hotta; Y Matsuzawa; R E Pratley; P A Tataranni Journal: J Clin Endocrinol Metab Date: 2001-05 Impact factor: 5.958
Authors: William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan Journal: N Engl J Med Date: 2002-02-07 Impact factor: 91.245
Authors: Robert S Lindsay; Tohru Funahashi; Robert L Hanson; Yuji Matsuzawa; Sachiyo Tanaka; P Antonio Tataranni; William C Knowler; Jonathan Krakoff Journal: Lancet Date: 2002-07-06 Impact factor: 79.321
Authors: Ethan Paddock; Maximilian G Hohenadel; Paolo Piaggi; Pavithra Vijayakumar; Robert L Hanson; William C Knowler; Jonathan Krakoff; Douglas C Chang Journal: Diabetologia Date: 2017-06-29 Impact factor: 10.122
Authors: Hau D Do; Vitool Lohsoonthorn; Wiroj Jiamjarasrangsi; Somrat Lertmaharit; Michelle A Williams Journal: Diabetes Res Clin Pract Date: 2010-05-13 Impact factor: 5.602
Authors: G Chen; X Zou; J Yao; Q Jiang; Y Zhang; M Tu; S Yang; S Xu; W Lin; H Huang; J Liang; L Li; L Lin Journal: J Endocrinol Invest Date: 2010-10-08 Impact factor: 4.256
Authors: O Osorio-Conles; M Guitart; J M Moreno-Navarrete; X Escoté; X Duran; J M Fernandez-Real; A M Gomez-Foix; S Fernández-Veledo; J Vendrell Journal: Mol Med Date: 2017-08-23 Impact factor: 6.354
Authors: Robert L Hanson; Rong Rong; Sayuko Kobes; Yunhua Li Muller; E Jennifer Weil; Jeffrey M Curtis; Robert G Nelson; Leslie J Baier Journal: Diabetes Date: 2015-02-09 Impact factor: 9.461